Autolus Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Autolus Therapeutics (AUTL).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$9Upside to Avg. PT+459.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 3, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$10
May 14, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$9→$10
Apr 9, 2026	Needham	Gil Blum	Maintained	Buy	$10
Mar 31, 2026	Mizuho	Salim Syed	PT Cut	Outperform	$12→$10
Mar 27, 2026	Needham	Gil Blum	Maintained	Buy	$10
Feb 17, 2026	HC Wainwright & Co.	Emily Bodnar	Initiate	Buy	$9
Jan 12, 2026	Needham	Gil Blum	PT Cut	Buy	$11→$10
Dec 29, 2025	Needham	Gil Blum	PT Raise	Buy	$10→$11
Dec 12, 2025	Needham	Gil Blum	Maintained	Buy	$10
Nov 3, 2025	Needham	Gil Blum	Maintained	Buy	$10
Oct 20, 2025	Needham	Gil Blum	Maintained	Buy	$10
Aug 13, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$6→$5
Jul 21, 2025	Needham	Gil Blum	Maintained	Buy	$10
Jun 12, 2025	Needham	Gil Blum	Maintained	Buy	$10
Apr 10, 2025	Needham	Gil Blum	Maintained	Buy	$10
Apr 1, 2025	Truist Securities	Asthika Goonewardene	PT Cut	Buy	$11→$10
Mar 21, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$8→$6
Jan 13, 2025	Needham	Gil Blum	Maintained	Buy	$10
Dec 9, 2024	Needham	Gil Blum	Maintained	Buy	$10
Dec 5, 2024	Needham	Gil Blum	Maintained	Buy	$10

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10

HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $9 to $10.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Autolus Therapeutics, Lowers Price Target to $10

Mizuho analyst Salim Syed maintains Autolus Therapeutics (NASDAQ:AUTL) with a Outperform and lowers the price target from $12 to $10.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Autolus Therapeutics with Buy Rating, Announces Price Target of $9

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Autolus Therapeutics (NASDAQ:AUTL) with a Buy rating and announces Price Target of $9.

Benzinga Newsdesk

Autolus Therapeutics PLC

ニュース

パートナーシップ

ベンジンガ・グローバル

Autolus Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10

PRO
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

PRO
Mizuho Maintains Outperform on Autolus Therapeutics, Lowers Price Target to $10

PRO
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

PRO
HC Wainwright & Co. Initiates Coverage On Autolus Therapeutics with Buy Rating, Announces Price Target of $9

People Also Watch

People Also Watch

Autolus Therapeutics PLC

ニュース

パートナーシップ

ベンジンガ・グローバル

Autolus Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

PROHC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10

PRONeedham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

PROMizuho Maintains Outperform on Autolus Therapeutics, Lowers Price Target to $10

PRONeedham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

PROHC Wainwright & Co. Initiates Coverage On Autolus Therapeutics with Buy Rating, Announces Price Target of $9

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10

PRO
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

PRO
Mizuho Maintains Outperform on Autolus Therapeutics, Lowers Price Target to $10

PRO
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

PRO
HC Wainwright & Co. Initiates Coverage On Autolus Therapeutics with Buy Rating, Announces Price Target of $9